10.15 USD
-0.38 (-3.61%)
10.09 USD
-0.06 (-0.59%)
TLRY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. TLRY may be in some trouble as it scores bad on both profitability and health. TLRY is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TLRY has reported negative net income.
In the past year TLRY has reported a negative cash flow from operations.
TLRY had negative earnings in each of the past 5 years.
In the past 5 years TLRY reported 4 times negative operating cash flow.
1.2 Ratios
TLRY has a Return On Assets of -103.13%. This is amonst the worse of the industry: TLRY underperforms 80.21% of its industry peers.
With a Return On Equity value of -139.41%, TLRY is not doing good in the industry: 68.75% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -103.13% | ||
| ROE | -139.41% | ||
| ROIC | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 28.69%, TLRY is in line with its industry, outperforming 55.73% of the companies in the same industry.
TLRY's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for TLRY so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.69% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
2. Health
2.1 Basic Checks
TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLRY has been increased compared to 1 year ago.
The number of shares outstanding for TLRY has been increased compared to 5 years ago.
Compared to 1 year ago, TLRY has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -1.42, we must say that TLRY is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TLRY (-1.42) is comparable to the rest of the industry.
TLRY has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
TLRY has a Debt to Equity ratio (0.18) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.42 |
ROIC/WACCN/A
WACC8.32%
2.3 Liquidity
TLRY has a Current Ratio of 2.62. This indicates that TLRY is financially healthy and has no problem in meeting its short term obligations.
TLRY's Current ratio of 2.62 is in line compared to the rest of the industry. TLRY outperforms 46.88% of its industry peers.
TLRY has a Quick Ratio of 1.56. This is a normal value and indicates that TLRY is financially healthy and should not expect problems in meeting its short term obligations.
TLRY has a Quick ratio of 1.56. This is in the lower half of the industry: TLRY underperforms 60.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.56 |
3. Growth
3.1 Past
TLRY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -6498.00%.
The Revenue has been growing slightly by 2.31% in the past year.
TLRY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.52% yearly.
EPS 1Y (TTM)-6498%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)2.31%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
3.2 Future
Based on estimates for the next years, TLRY will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.94% on average per year.
TLRY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.31% yearly.
EPS Next Y99.61%
EPS Next 2Y41.34%
EPS Next 3Y25.98%
EPS Next 5Y14.94%
Revenue Next Year3.65%
Revenue Next 2Y4.08%
Revenue Next 3Y4.24%
Revenue Next 5Y4.31%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TLRY. In the last year negative earnings were reported.
Also next year TLRY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TLRY is valued a bit cheaper than 78.65% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 27.88 |
4.3 Compensation for Growth
A more expensive valuation may be justified as TLRY's earnings are expected to grow with 25.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.34%
EPS Next 3Y25.98%
5. Dividend
5.1 Amount
TLRY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
10.15
-0.38 (-3.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners10.33%
Inst Owner Change21.14%
Ins Owners0.36%
Ins Owner Change2.64%
Market Cap1.18B
Revenue(TTM)830.77M
Net Income(TTM)-2.15B
Analysts71.25
Price Target17.2 (69.46%)
Short Float %N/A
Short Ratio1.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2631.48%
Min EPS beat(2)-5362.97%
Max EPS beat(2)100%
EPS beat(4)1
Avg EPS beat(4)-1385.84%
Min EPS beat(4)-5362.97%
Max EPS beat(4)100%
EPS beat(8)2
Avg EPS beat(8)-708.23%
EPS beat(12)2
Avg EPS beat(12)-746.7%
EPS beat(16)4
Avg EPS beat(16)-606.4%
Revenue beat(2)1
Avg Revenue beat(2)-3.41%
Min Revenue beat(2)-7.23%
Max Revenue beat(2)0.41%
Revenue beat(4)1
Avg Revenue beat(4)-6.19%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)0.41%
Revenue beat(8)1
Avg Revenue beat(8)-5.71%
Revenue beat(12)2
Avg Revenue beat(12)-3.59%
Revenue beat(16)2
Avg Revenue beat(16)-3.93%
PT rev (1m)810.09%
PT rev (3m)1562.73%
EPS NQ rev (1m)-900%
EPS NQ rev (3m)-788.89%
EPS NY rev (1m)-19.05%
EPS NY rev (3m)54.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.01%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.42 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.76 | ||
| P/tB | 1.54 | ||
| EV/EBITDA | 27.88 |
EPS(TTM)-13.2
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS7.16
BVpS13.28
TBVpS6.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -103.13% | ||
| ROE | -139.41% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.69% | ||
| FCFM | N/A |
ROA(3y)-48.32%
ROA(5y)-36.47%
ROE(3y)-65.2%
ROE(5y)-55.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.36%
GM growth 5YN/A
F-Score3
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 6.5 | ||
| Cap/Depr | 30.45% | ||
| Cap/Sales | 4.3% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.56 | ||
| Altman-Z | -1.42 |
F-Score3
WACC8.32%
ROIC/WACCN/A
Cap/Depr(3y)21.23%
Cap/Depr(5y)65.01%
Cap/Sales(3y)3.68%
Cap/Sales(5y)7.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6498%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y99.61%
EPS Next 2Y41.34%
EPS Next 3Y25.98%
EPS Next 5Y14.94%
Revenue 1Y (TTM)2.31%
Revenue growth 3Y9.34%
Revenue growth 5Y37.52%
Sales Q2Q%4.73%
Revenue Next Year3.65%
Revenue Next 2Y4.08%
Revenue Next 3Y4.24%
Revenue Next 5Y4.31%
EBIT growth 1Y28.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year109.61%
EBIT Next 3Y29.12%
EBIT Next 5Y17.36%
FCF growth 1Y-688.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-258.17%
OCF growth 3YN/A
OCF growth 5YN/A
TILRAY BRANDS INC / TLRY FAQ
Can you provide the ChartMill fundamental rating for TILRAY BRANDS INC?
ChartMill assigns a fundamental rating of 2 / 10 to TLRY.
What is the valuation status of TILRAY BRANDS INC (TLRY) stock?
ChartMill assigns a valuation rating of 1 / 10 to TILRAY BRANDS INC (TLRY). This can be considered as Overvalued.
How profitable is TILRAY BRANDS INC (TLRY) stock?
TILRAY BRANDS INC (TLRY) has a profitability rating of 1 / 10.
How financially healthy is TILRAY BRANDS INC?
The financial health rating of TILRAY BRANDS INC (TLRY) is 3 / 10.